NewAmsterdam Pharma Company N.V. — Cyborg Score 6/10
Solid
Cardiovascular Drugs
Strategic Profile
Obicetrapib is being investigated in multiple clinical trials for cardiovascular disease applications and in Phase 2a clinical trial for Alzheimer's disease. The company maintains a focused pipeline centered on addressing cardiometabolic disease with oral therapies where existing treatment options are suboptimal. Strategic positioning emphasizes both cardiovascular and neurodegenerative indications with a single lead asset.
Cyborg Score Rationale
Late-stage clinical company with a focused pipeline and clear unmet need focus. Trading well below analyst fair value estimates suggests market skepticism about development success, though analyst coverage and institutional backing provide credibility. Pre-revenue status and single-asset concentration create execution risk.
Top Insights
Single lead asset (Obicetrapib) pursuing dual indications—cardiovascular disease and Alzheimer's disease—concentrating both opportunity and execution risk
Company trades at significant discount to analyst valuations, indicating market pricing in elevated development risk
Company actively hiring non-executive talent (February 2026), signaling operational build-out ahead of potential regulatory milestones
Focused cardiometabolic strategy targets populations where current therapies fail—a large but competitive market segment
Named Competitors
Anacetrapib — CETP inhibitor for LDL-C lowering
Inclisiran — PCSK9 inhibitor for LDL-C reduction
Repatha — PCSK9 inhibitor for cardiovascular risk reduction
Statins — Standard of care for LDL-C lowering
Recent Developments
(February 2026) Granted inducement share options to four non-executive new hires under 2024 Inducement Plan
Open the full interactive NewAmsterdam Pharma Company N.V. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.